These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 850907)

  • 41. The binding of plasminogen to fibrin: evidence for plasminogen-bridging.
    Garman AJ; Smith RA
    Thromb Res; 1982 Aug; 27(3):311-20. PubMed ID: 6814006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Localization of the binding sites of porcine tissue-type plasminogen activator and plasminogen to heparin.
    Soeda S; Kakiki M; Shimeno H; Nagamatsu A
    Biochim Biophys Acta; 1987 Dec; 916(3):279-87. PubMed ID: 3120775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography.
    Vlakh EG; Platonova GA; Vlasov GP; Kasper C; Tappe A; Kretzmer G; Tennikova TB
    J Chromatogr A; 2003 Apr; 992(1-2):109-19. PubMed ID: 12735467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin.
    Tran-Thang C; Kruithof EK; Atkinson J; Bachmann F
    Eur J Biochem; 1986 Nov; 160(3):599-604. PubMed ID: 2946579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis.
    Holvoet P; Lijnen HR; Collen D
    Eur J Biochem; 1986 May; 157(1):65-9. PubMed ID: 2940088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The relationship between the lysine and the p-aminobenzamidine binding sites on human plasminogen.
    Holleman WH; Andres WW; Weiss LJ
    Thromb Res; 1975 Nov; 7(5):683-93. PubMed ID: 1209557
    [No Abstract]   [Full Text] [Related]  

  • 47. A covalent molecular weight approximately 92,000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains.
    Robbins KC; Boreisha IG
    Biochemistry; 1987 Jul; 26(15):4661-7. PubMed ID: 3117104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.
    Thorsen S
    Biochim Biophys Acta; 1975 May; 393(1):55-65. PubMed ID: 124594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Proteolytic activity of the Glu-plasminogen complex with fibrinogen fragment E].
    Skomorovskaia EV; Grinenko TV; Kudinov SA; Zolotareva EN
    Biokhimiia; 1991 Mar; 56(3):458-66. PubMed ID: 1883906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Purification and characterization of a novel fibrinolytic enzyme from Streptomyces spp.
    Wang J; Wang M; Wang Y
    Chin J Biotechnol; 1999; 15(2):83-9. PubMed ID: 10719627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression, purification, and characterization of the recombinant kringle 1 domain from tissue-type plasminogen activator.
    DeSerrano VS; Menhart N; Castellino FJ
    Arch Biochem Biophys; 1992 Apr; 294(1):282-90. PubMed ID: 1550352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Studies on plasminogen. IX. Purification of human plasminogen from Cohn fraction 3 by affinity chromatography.
    Liu TH; Mertz ET
    Can J Biochem; 1971 Sep; 49(9):1055-61. PubMed ID: 5159592
    [No Abstract]   [Full Text] [Related]  

  • 54. Inhibition of fibrinolysis by lipoprotein(a).
    Anglés-Cano E; de la Peña Díaz A; Loyau S
    Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of heparin on the affinity chromatography of plasminogen. Demonstration of heparin-plasminogen interaction.
    Hatton MW; Regoeczi E
    Biochim Biophys Acta; 1975 Apr; 386(2):451-60. PubMed ID: 1138880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elimination of the Cys558-Cys566 bond in Lys78-plasminogen--effect on activation and fibrin interaction.
    Linde V; Nielsen LS; Foster DC; Petersen LC
    Eur J Biochem; 1998 Jan; 251(1-2):472-9. PubMed ID: 9492320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A rapid and simple method for the separation of four molecular forms of human plasminogen.
    Nieuwenhuizen W; Traas DW
    Thromb Haemost; 1989 Apr; 61(2):208-10. PubMed ID: 2749595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen.
    Grailhe P; Nieuwenhuizen W; Anglés-Cano E
    Eur J Biochem; 1994 Feb; 219(3):961-7. PubMed ID: 8112348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
    Silva MM; Thelwell C; Williams SC; Longstaff C
    J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2).
    Ritchie H; Lawrie LC; Mosesson MW; Booth NA
    Ann N Y Acad Sci; 2001; 936():215-8. PubMed ID: 11460477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.